MFDS — authorised 1 February 2023
- Marketing authorisation holder: GLAXOSMITHKLINE
- Status: likely_approved
🇰🇷 Jesduvroq in South Korea
MFDS authorised Jesduvroq on 1 February 2023
Marketing authorisation
Jesduvroq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in South Korea
Frequently asked questions
Is Jesduvroq approved in South Korea?
Yes. MFDS authorised it on 1 February 2023.
Who is the marketing authorisation holder for Jesduvroq in South Korea?
GLAXOSMITHKLINE holds the South Korean marketing authorisation.